Doctronic
The board is calling for the immediate suspension of the state's AI-enabled prescription renewal program, citing patient safety concerns and lack of clinical oversight.
The Series B marks the company's third funding round in less than a year.
The state is piloting a program with Doctronic that allows AI to legally participate in medical decision-making for patients with chronic conditions in need of prescription renewals.
The funds will be used to expand its direct-to-consumer services and grow partnerships with payers and health systems.